📊 CNTX Key Takeaways
Is Context Therapeutics Inc. (CNTX) a Good Investment?
Context Therapeutics is an early-stage pharmaceutical company with minimal revenue ($2.2M) and significant ongoing losses (-$8.7M net income), demonstrating no path to profitability or clinical viability visible in these fundamentals. While the balance sheet is fortress-like with $54.5M cash and zero debt providing 4-5 years of operational runway, the company has not yet proven commercial product potential. The marginal improvements in loss metrics represent movement toward less negative, not positive fundamentals.
Context Therapeutics shows strong balance-sheet liquidity with $76.94M of cash, no long-term debt, and very low liabilities relative to equity, which supports near-term operating flexibility. However, the core fundamentals remain weak: revenue is still very small at $2.24M, operating and net losses are extremely large relative to sales, and free cash flow is deeply negative, indicating the business is not yet demonstrating scalable or durable profitability. The revenue growth is notable, but the quality of that growth appears low until it translates into materially improved margins and reduced cash burn.
Context Therapeutics Inc. Key Strengths (CNTX)
- Exceptionally strong balance sheet with $54.5M cash and zero debt (Debt/Equity 0.00x)
- Excellent liquidity position (8.96x current ratio) provides operational flexibility
- Revenue growth of 112.7% YoY and improving loss margins demonstrate operational progress at micro-scale
- Very strong liquidity profile with $76.94M cash and 13.10x current and quick ratios
- Debt-free capital structure reduces financial risk and interest burden
- Revenue grew 112.7% year over year, indicating some top-line momentum
CNTX Stock Risks: Context Therapeutics Inc. Investment Risks
- Minimal revenue base ($2.2M) indicates no validated commercial products; company remains pre-commercialization
- Negative operating cash flow (-$11.4M annually) indicates significant R&D spending without revenue generation to offset
- Pharmaceutical sector execution risk: typical clinical failure rates and years to regulatory approval create high uncertainty
- Cash runway of only 4-5 years at current burn rate necessitates additional financing or revenue acceleration
- Operating margin of -417.8% and net margin of -388.2% show severe unprofitability with no near-term resolution visible
- Operating margin of -1158.1% and net margin of -1032.9% show the business is far from economic sustainability
- Negative operating cash flow and free cash flow of about $17.5M indicate ongoing cash burn
- Revenue base remains too small relative to cost structure, raising questions about growth quality and scalability
Key Metrics to Watch
- Clinical trial progress and regulatory milestones for pipeline candidates
- Cash burn rate trends and path to breakeven
- Revenue growth acceleration and gross margin expansion upon product commercialization
- Operating cash flow trajectory toward positive territory
- Quarterly operating cash burn relative to cash balance
- Revenue growth alongside improvement in operating loss and net margin
Context Therapeutics Inc. (CNTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.96x current ratio provides a solid financial cushion.
CNTX Profit Margin, ROE & Profitability Analysis
CNTX vs Healthcare Sector: How Context Therapeutics Inc. Compares
How Context Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Context Therapeutics Inc. Stock Overvalued? CNTX Valuation Analysis 2026
Based on fundamental analysis, Context Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Context Therapeutics Inc. Balance Sheet: CNTX Debt, Cash & Liquidity
CNTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Context Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.46 indicates the company is currently unprofitable.
CNTX Revenue Growth, EPS Growth & YoY Performance
Context Therapeutics Inc. Dividends, Buybacks & Capital Allocation
CNTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Context Therapeutics Inc. (CIK: 0001842952)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNTX
What is the AI rating for CNTX?
Context Therapeutics Inc. (CNTX) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNTX's key strengths?
Claude: Exceptionally strong balance sheet with $54.5M cash and zero debt (Debt/Equity 0.00x). Excellent liquidity position (8.96x current ratio) provides operational flexibility. ChatGPT: Very strong liquidity profile with $76.94M cash and 13.10x current and quick ratios. Debt-free capital structure reduces financial risk and interest burden.
What are the risks of investing in CNTX?
Claude: Minimal revenue base ($2.2M) indicates no validated commercial products; company remains pre-commercialization. Negative operating cash flow (-$11.4M annually) indicates significant R&D spending without revenue generation to offset. ChatGPT: Operating margin of -1158.1% and net margin of -1032.9% show the business is far from economic sustainability. Negative operating cash flow and free cash flow of about $17.5M indicate ongoing cash burn.
What is CNTX's revenue and growth?
Context Therapeutics Inc. reported revenue of $2.2M.
Does CNTX pay dividends?
Context Therapeutics Inc. does not currently pay dividends.
Where can I find CNTX SEC filings?
Official SEC filings for Context Therapeutics Inc. (CIK: 0001842952) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNTX's EPS?
Context Therapeutics Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CNTX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Context Therapeutics Inc. has a C grade with 77% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CNTX stock overvalued or undervalued?
Valuation metrics for CNTX: ROE of -16.6% (sector avg: 15%), net margin of -388.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CNTX's AI grade for 2026?
Our dual AI analysis gives Context Therapeutics Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CNTX's free cash flow?
Context Therapeutics Inc.'s operating cash flow is $-11.4M, with capital expenditures of $37.3K. FCF margin is -512.8%.
How does CNTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -388.2% (avg: 12%), ROE -16.6% (avg: 15%), current ratio 8.96 (avg: 2).